Our first week of The Future of Cannabis was certainly an eventful. When we launched our four-week program, Equities.com and Viridian Capital Advisors set out to help investors better understand the opportunity that was being presented to them in the cannabis industry by gathering leading expert perspectives, objective news coverage, and comprehensive market research. The first week certainly was jam-packed with informative features, insightful interviews and comprehensive financial research.
To learn more about The Future of Cannabis program, we encourage you to read What is The Future of Cannabis?
Here’s a recap of everything we published in our Week One focus on the current state of the broader cannabis market.
Week One: Macro Perspective and Overview
Cannabis: A Social, Political, and Business Revolution has Begun: In this feature, we outline why the cannabis market deserves the attention of investors and the broader business community. A confluence of macro-forces, including the increasing number of jurisdictions considering the legalization of cannabis and the growing majority of the population in favor of it, is creating an environment where this industry can really flourish to become an economic powerhouse.
5 Things Investors Need to Know About Cannabis: Our friends at Visual Capitalist helped us present some key data and facts that everyone should know about the cannabis market. The infographic is easy on the eyes and is simple to understand. Be sure to check it out and pass it along to your friends.
Expert Interviews: We wanted to serve as a platform for leading voices in the cannabis market to provide their perspectives and to encourage dialogue about the industry. Here’s who we heard from this week
- Ambassador Ned L. Siegel: This is What Separates the Cannabis Opportunity from Everything Else in the Market
- Colorado’s Brian Vicente: What’s Next for the Silicon Valley of Marijuana?
- Sean Kiernan: "We're the Ones Who Are Blocked" About Treating PTSD with Cannabis
- This Catalyst Shows Why the Cannabis Industry is Just Getting Started – with Joel Anderson
- Defining the Cannabis Opportunity – with Scott Greiper
- The Best Performing Sectors of the Cannabis Market – with Scott Greiper
- The Most Important Quality a Cannabis Company Has to Have – with Ambassador Ned L. Siegel
- Applying Best Practices in the Cannabis Space – with Ambassador Ned L. Siegel
- Why Cannabis is an Important Issue for Everyone – Sean Kiernan of Weed for Warriors
Sector Research: Viridian Capital Advisors knows the cannabis as well as anyone. Each week they’ll be providing a detailed market research report, and this week they’ve covered the key big themes of the cannabis industry.
Names to Know in the Cannabis Space
- Medbox, Inc. (MDBX): Medbox, Inc., a leader in the rapidly emerging cannabis sector, provides specialized services to operators of dispensaries, cultivation centers, manufacturers and research facilities in those states where approved. Through trusted clients and affiliates, the company promotes efficient, consistent, high quality products that are priced right, readily available and safely packaged.
- Heliospectra (HLSPY): Heliospectra AB specializes in intelligent lighting technology for plant research and greenhouse cultivation. The Company's lighting system provides an effective and durable technology for cultivating greenhouse and indoor plants by combining several different groups of versatile light emitting diodes (LEDs) with optics, remote sensing techniques, and a robust heat dissipation solution. This proprietary setup gives growers the ability to control the intensity and wavelengths of the light emitted, creating a spectrum specifically adjusted to different plant species and growth stages to better facilitate photosynthesis.
- MyDx, Inc. (MYDX): MyDx, Inc. is a science and technology company based in San Diego, California whose mission is to help people Trust & Verify™ what they put into their minds and bodies. The Company has developed MyDx™, an affordable portable analyzer that provides real-time chemical analysis and fits in the palm of your hands. MyDx™ leverages over a decade of established electronic nose technology to measure chemicals of interest and has four sensors being developed in its lab that are compatible with the MyDx™ Analyzer and App.
- MassRoots, Inc. (MSRT): MassRoots is one of the largest and most active communities of cannabis consumers with over 625,000 users. It is proud to be affiliated with the leading organizations in the cannabis industry, including the ArcView Group and National Cannabis Industry Association.
- CannaSys, Inc. (OTCQB:MJTK): CannaSys is a leading technology solutions provider to the regulated cannabis industry. Its core products are delivered software as a service to facilitate point-of-purchase transactions, customer relationship marketing solutions, and cannabis laboratory information management systems. CannaSys plans to develop, acquire, and build partnerships in order to bring additional solutions to market in both established and developing medical and recreational cannabis states.
Week Two Preview: The Biotech/Pharma Investment Opportunity in Cannabis
As we move into the second week of our program, we begin to dig into specific growth areas of the overall cannabis opportunity. Next week, we'll be examining the most developed segment of this market to date, which is the biotech and pharmaceuticals sector. One of the most compelling catalysts of the cannabis market is the potential medical benefits that can be derived from the application of cannabinoids to treat diseases and alleviate symptoms. There are already innovative companies making major headway here. Be sure to comeback next week as we dive in.
You can read more from our special program The Future of Cannabis here. To find out why Equities.com and Viridian Capital Advisors launched this program, be sure to read What is The Future of Cannabis? This program was made possible by the support of our sponsors.Click here for a full list of our sponsors.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer